{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:19:02Z","timestamp":1778253542861,"version":"3.51.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006190","name":"US Department of Veterans Affairs Office of Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA207530"],"award-info":[{"award-number":["R01CA207530"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development, VA Office of Research and Development","doi-asserted-by":"publisher","award":["I01BX001799"],"award-info":[{"award-number":["I01BX001799"]}],"id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.04.015","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T02:46:08Z","timestamp":1650595568000},"page":"659-665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3380-5326","authenticated-orcid":false,"given":"Suheil Albert","family":"Atallah-Yunes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Utpal P.","family":"Dav\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.015_bib0001","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin Modifications and Their Function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.clml.2022.04.015_bib0002","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.clml.2022.04.015_bib0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.biochem.70.1.81","article-title":"Histone Acetyltransferases","volume":"70","author":"Roth","year":"2001","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.clml.2022.04.015_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbagrm.2008.06.005","article-title":"Chemical mechanisms of histone lysine and arginine modifications","volume":"1789","author":"Smith","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms"},{"key":"10.1016\/j.clml.2022.04.015_bib0005","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2022.04.015_bib0006","article-title":"Recent Update of HDAC Inhibitors in Lymphoma","volume":"8","author":"Chen","year":"2020","journal-title":"Frontiers in cell and developmental biology"},{"key":"10.1016\/j.clml.2022.04.015_bib0007","doi-asserted-by":"crossref","first-page":"424","DOI":"10.7150\/ijms.30154","article-title":"Histone Deacetylases (HDACs) guided novel therapies for T-cell lymphomas","volume":"16","author":"Zhang","year":"2019","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clml.2022.04.015_bib0008","doi-asserted-by":"crossref","unstructured":"Bates SE, Zhan Z, Steadman K, et\u00a0al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. 2010;148:256-67.","DOI":"10.1111\/j.1365-2141.2009.07954.x"},{"key":"10.1016\/j.clml.2022.04.015_bib0009","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/leu.2016.357","article-title":"Histone deacetylase inhibitors interrupt HSP90\u2022RASGRP1 and HSP90\u2022CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells","volume":"31","author":"Ding","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.015_bib0010","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/onc.2011.533","article-title":"Acetylation controls Notch3 stability and function in T-cell leukemia","volume":"31","author":"Palermo","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2022.04.015_bib0011","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4161\/epi.3.3.6253","article-title":"A work in progress: The clinical development of histone deacetylase inhibitor","volume":"3","author":"Marsoni","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.clml.2022.04.015_bib0012","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","article-title":"Targeting histone deacetylases in T-cell lymphoma","volume":"58","author":"Moskowitz","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.04.015_bib0013","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0014","first-page":"47","article-title":"The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management","volume":"70","author":"Marchi","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2022.04.015_bib0015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase I study","volume":"134","author":"O'Connor","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0017","doi-asserted-by":"crossref","unstructured":"Bachy E, Camus V, Thieblemont C, et\u00a0al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP Phase III Study (Conducted by LYSA). 2022;40:242-51.","DOI":"10.1200\/JCO.21.01815"},{"key":"10.1016\/j.clml.2022.04.015_bib0018","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0019","doi-asserted-by":"crossref","first-page":"e416","DOI":"10.3324\/haematol.2018.187617","article-title":"A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma","volume":"103","author":"Strati","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.015_bib0020","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.015_bib0021","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.clml.2022.04.015_bib0022","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.clml.2022.04.015_bib0023","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0024","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.04.015_bib0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.04.015_bib0026","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","article-title":"IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0027","doi-asserted-by":"crossref","first-page":"e23761","DOI":"10.1371\/journal.pone.0023761","article-title":"The transmembrane adaptor protein SIT inhibits TCR-mediated signaling","volume":"6","author":"Arndt","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.04.015_bib0028","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2006.08.005","article-title":"MAPK-specific tyrosine phosphatases: new targets for drug discovery?","volume":"27","author":"Barr","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clml.2022.04.015_bib0029","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-017-0085-8","article-title":"Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Willemsen","year":"2017","journal-title":"Biomarker Research"},{"key":"10.1016\/j.clml.2022.04.015_bib0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.04.015_bib0031","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2022.04.015_bib0032","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1084\/jem.20100204","article-title":"DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas","volume":"207","author":"Lai","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2022.04.015_bib0033","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/bcj.2014.83","article-title":"Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice","volume":"4","author":"Muto","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.04.015_bib0034","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12185-016-2159-z","article-title":"BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma","volume":"105","author":"Nishizawa","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2022.04.015_bib0035","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/PAS.0b013e31817f123e","article-title":"Peripheral T-cell lymphoma with follicular T-cell markers","volume":"32","author":"Rodr\u00edguez-Pinilla","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2022.04.015_bib0036","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0037","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A Mutations in Human T-Cell Lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.015_bib0038","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0039","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation","volume":"44","author":"Challen","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2022.04.015_bib0040","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.stem.2014.06.018","article-title":"Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells","volume":"15","author":"Challen","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2022.04.015_bib0041","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2016.29","article-title":"DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice","volume":"30","author":"Scourzic","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.015_bib0042","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.015_bib0043","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.04.015_bib0044","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2022.04.015_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","article-title":"Genetic landscape and classification of peripheral T Cell lymphomas","volume":"19","author":"Sandell","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2022.04.015_bib0046","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2022.04.015_bib0047","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.04.015_bib0048","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.04.015_bib0049","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0050","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0051","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0052","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood.2019003385","article-title":"Subclassifying peripheral T-cell lymphoma NOS","volume":"134","author":"Carbone","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0053","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-021-00224-3","article-title":"Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas","volume":"10","author":"Yoon","year":"2021","journal-title":"Experimental hematology & oncology"},{"key":"10.1016\/j.clml.2022.04.015_bib0054","doi-asserted-by":"crossref","unstructured":"Tiacci E, Venanzi A, Ascani S, et\u00a0al. High-risk clonal hematopoiesis as the origin of AITL and NPM1-mutated AML. 2018;379:981-4.","DOI":"10.1056\/NEJMc1806413"},{"key":"10.1016\/j.clml.2022.04.015_bib0055","doi-asserted-by":"crossref","unstructured":"Tobiasson M, Pandzic T, Cavelier L, et\u00a0al. Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1\u2013azacitidine induces only lymphoma remission. 2019;60:3316-9.","DOI":"10.1080\/10428194.2019.1627541"},{"key":"10.1016\/j.clml.2022.04.015_bib0056","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hon.2319","article-title":"Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma","volume":"35","author":"Saillard","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0057","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","article-title":"Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms","volume":"4","author":"Lewis","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.04.015_bib0058","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0059","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1158\/1078-0432.CCR-19-2152","article-title":"Romidepsin plus liposomal doxorubicin is safe and effective in patients with relapsed or refractory T-Cell lymphoma: results of a phase I dose-escalation study","volume":"26","author":"Vu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.04.015_bib0060","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase II study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0061","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","article-title":"Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase Ib\/II study","volume":"2","author":"Dupuis","year":"2015","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.clml.2022.04.015_bib0062","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V126.23.253.253","article-title":"Safe and effective treatment of patients with peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC inhibitor, belinostat, in combination with CHOP: results of the Bel-CHOP phase I trial","volume":"126","author":"Johnston","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0063","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase I trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.04.015_bib0064","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The Combination of Duvelisib, a PI3K-\u03b4,\u03b3 Inhibitor, and Romidepsin Is Highly Active in Relapsed\/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase I Combination Studies with Expansion Cohorts","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.04.015_bib0065","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1200\/jco.2015.33.15_suppl.8521","article-title":"A phase I\/II trial of the combination of romidepsin and lenalidomide in patients with relapsed\/refractory lymphoma and myeloma: Activity in T-cell lymphoma","volume":"33","author":"Mehta-Shah","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0066","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase II clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.015_bib0067","doi-asserted-by":"crossref","unstructured":"Pro B, Brammer JE, Casulo C, et\u00a0al. Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase II primo trial: Dose optimization efficacy update and expansion phase initial results. 2020;136:38-9.","DOI":"10.1182\/blood-2020-140412"},{"key":"10.1016\/j.clml.2022.04.015_bib0068","series-title":"Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL)","author":"Ruan","year":"2021"},{"key":"10.1016\/j.clml.2022.04.015_bib0069","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Koch R, Mehta-Shah N, et\u00a0al. In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4, \u03b3 inhibitor, in combination with romidepsin or bortezomib in relapsed\/refractory T-cell lymphoma. 2017;130:819.","DOI":"10.1182\/blood.V130.Suppl_1.819.819"},{"key":"10.1016\/j.clml.2022.04.015_bib0070","doi-asserted-by":"crossref","unstructured":"Mehta-Shah N, Moskowitz AJ, Lunning M, et\u00a0al. A phase Ib\/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed\/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas. 2016;128:2991.","DOI":"10.1182\/blood.V128.22.2991.2991"},{"key":"10.1016\/j.clml.2022.04.015_bib0071","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood.V124.21.4493.4493","article-title":"The investigational aurora A kinase inhibitor alisertib exhibits broad activity in preclinical models of T-cell lymphoma and is highly synergistic with romidepsin","volume":"124","author":"Zullo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0072","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1158\/1078-0432.CCR-13-1906","article-title":"Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma","volume":"19","author":"Oki","year":"2013","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.clml.2022.04.015_bib0073","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.015_bib0074","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2021-145495","article-title":"High rates of remission with the initial treatment of oral azacitidine plus CHOP for Peripheral T-Cell Lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study","volume":"138","author":"Ruan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0075","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase II trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.015_bib0076","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0077","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hon.2320","article-title":"Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma","volume":"35","author":"Pro","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.04.015_bib0078","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428194.2018.1515937","article-title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study\u2020","volume":"60","author":"Reiman","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.04.015_bib0079","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.04.015_bib0080","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","article-title":"Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase II trial","volume":"2","author":"Tan","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.04.015_bib0081","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:34Z","timestamp":1761871234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2152265022001318"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}